SCHEMBL14422919

SCHEMBL14422919

CNC(=O)c1cc(Oc2cccc(NC(=O)CC(=O)Nc3ccc(C)c(Cl)c3)c2)ccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.62
BRAF P15056 6/20 0.59
RAF1 P04049 6/20 0.59
CDK8 P49336 2/20 0.53
KDR P35968 6/20 0.53
MAPK14 Q16539 4/20 0.53
AURKB Q96GD4 3/20 0.53
ABL1 P00519 3/20 0.53
EPHA2 P29317 3/20 0.53
MAP3K20 Q9NYL2 3/20 0.53
PLK4 O00444 2/20 0.53
AURKA O14965 2/20 0.53
MAPK13 O15264 2/20 0.53
MAP4K4 O95819 2/20 0.53
LCK P06239 2/20 0.53
FYN P06241 2/20 0.53
LYN P07948 2/20 0.53
SRC P12931 2/20 0.53
RPS6KB1 P23443 2/20 0.53
AXL P30530 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14422928 0.92 RAF1 (0.61) RETBRAFRAF1CDK8KDR
SCHEMBL14422922 0.92 RET (0.67) RETBRAFRAF1CDK8KDR
SCHEMBL14422925 0.91 RET (0.58) RETBRAFRAF1CDK8KDR
SCHEMBL5635415 0.85 RET (0.86) RETBRAFRAF1CDK8KDR
SCHEMBL14422930 0.84 RAF1 (0.66) RETBRAFRAF1CDK8KDR
SCHEMBL14422931 0.83 RAF1 (0.60) RETBRAFRAF1CDK8KDR
SCHEMBL14422926 0.82 KDR (0.71) RETBRAFRAF1CDK8KDR
SCHEMBL14422927 0.82 RAF1 (0.65) RETBRAFRAF1CDK8KDR
SCHEMBL6014190 0.82 KDR (0.59) RETBRAFRAF1CDK8KDR
SCHEMBL14422924 0.81 KDR (0.75) RETBRAFRAF1CDK8KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213374-A1 Malonamide Derivatives MERCK PATENT GMBH (DE) 2007-09-13 US disclosed
US-20070213374-A1 Malonamide Derivatives MERCK PATENT GMBH (DE) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213374-A1 Malonamide Derivatives RAF1, BRAF, ARAF RET 350/4885BRAF 2/4885RAF1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.